Annovis

Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, for Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

CardiaCures

CardiaCures is developing a repeatable, efficient multi-drug pipeline to reinvent personalized medicine for atrial fibrillation and heart disease. Focused on software-linked drugs being a new category of medicine. Dosing software named in the FDA-approved label - developed, submitted, and reimbursed as a drug. Founded by a team of people who helped write the regulatory science

AACT

AACT Inc is a precision oncology and infectious disease therapeutics company founded in 2018. The Company has developed a distinctive multi-indication platform of selective kinase inhibitors targeting three major therapeutic markets: oncology, viral infections (including pandemic preparedness), and critical care (ARDS).